IDH1 and central nervous system cancer: Preliminary data from the clinical trials in acute myeloid leukemia (AML) suggest that there is benefit of mutant IDH2 inhibition and lowering of 2HG concentration22, however no data are yet available from clinical trials in mutant IDH1 glioma patients.